References
- Cerny T, Borisch B, Introna M, et al. Mechanism of action of rituximab. Anticancer Drugs. 2002;13(2):S3–S10. doi:10.1097/00001813-200211002-00002.
- Paul F, Cartron G. Infusion-related reactions to rituximab: frequency, mechanisms and predictors. Expert Rev Clin Immunol. 2019;15(4):383–389. doi:10.1080/1744666X.2019.1562905.
- Kasi PM, Tawbi HA, Oddis CV, et al. Clinical review: serious adverse events associated with the use of rituximab – a critical care perspective. Crit Care. 2012;16(4):231. doi:10.1186/cc11304.
- D'Arena G, Simeon V, Laurenti L, et al. Adverse drug reactions after intravenous rituximab infusion are more common in hematologic malignancies than in autoimmune disorders and can be predicted by the combination of few clinical and laboratory parameters: results from a retrospective, multicenter study of 374 patients. Leuk Lymphoma. 2017;58(11):2633–2641. doi:10.1080/10428194.2017.1306648.
- Hayama T, Miura K, Uchiike A, et al. A clinical prediction model for infusion-related reactions to rituximab in patients with B cell lymphomas. Int J Clin Pharm. 2017;39(2):380–385. doi:10.1007/s11096-017-0429-3.
- Jung JW, Kang HR, Lee SH, et al. The incidence and risk factors of infusion-related reactions to rituximab for treating B cell malignancies in a single tertiary hospital. Oncology. 2014;86(3):127–134. doi:10.1159/000357711.
- Ohata S, Takenaka K, Sugiyama D, et al. Bone marrow infiltration is a distinctive risk factor for rituximab infusion-related reactions in CD20-positive B-cell non-Hodgkin lymphoma. Adv Hematol. 2022;2022:3688727. doi:10.1155/2022/3688727.
- Chung CH. Managing premedications and the risk for reactions to infusional monoclonal antibody therapy. Oncologist. 2008;13(6):725–732. doi:10.1634/theoncologist.2008-0012.
- Freeman CL, Dixon M, Houghton R, et al. Role of CD20 expression and other pre-treatment risk factors in the development of infusion-related reactions in patients with CLL treated with obinutuzumab. Leukemia. 2016;30(8):1763–1766. doi:10.1038/leu.2016.41.
- Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239–245. doi:10.1038/clpt.1981.154.
- Common Terminology Criteria for Adverse Events (CTCAE). Version 5. US Department of Health and Human Services, National Institutes of Health, National Cancer Institute; 2017.
- Rituxan (rituximab). Prescribing information. South San Francisco (CA): Genentech Inc; 2021.
- Kimby E. Tolerability and safety of rituximab (MabThera). Cancer Treat Rev. 2005;31(6):456–473. doi:10.1016/j.ctrv.2005.05.007.
- Winkler U, Jensen M, Manzke O, et al. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDECC2B8). Blood. 1999 1;94(7):2217–2224. doi:10.1182/blood.V94.7.2217.419k02_2217_2224.
- Tachi T, Yasuda M, Usui K, et al. Risk factors for developing infusion reaction after rituximab administration in patients with B-cell non-Hodgkin’s lymphoma. Pharmazie. 2015;70(10):674–677.
- Lang DS, Keefe DM, Schultz T, et al. Predictors of acute adverse events from rapid rituximab infusion. Support Care Cancer. 2013;21(8):2315–2320. doi:10.1007/s00520-013-1788-5.
- Cho KM, Keam B, Ha H, et al. Clinical significance of rituximab infusion-related reaction in diffuse large B-cell lymphoma patients receiving R-CHOP. Korean J Intern Med. 2019;34(4):885–893. Jul doi:10.3904/kjim.2017.036.
- Kotchetkov R, McLean J, Nay D, et al. Premedication with montelukast and rupatadine decreased rituximab infusion time, rate, severity of reactions and use of rescue medications. Int J Cancer. 2020;147(7):1979–1986. Oct 1 doi:10.1002/ijc.32985.
- Ding J, Leng Z, Gu H, et al. A novel prednisone premedication protocol significantly decreases infusion-related reactions of rituximab in newly diagnosed diffuse large B-cell lymphoma. Oncol Lett. 2023;25(6):258. Apr 28 doi:10.3892/ol.2023.13844.